• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Tau重复结构域在聚集过程中的阶段和构象及其对神经元毒性的影响。

Stages and conformations of the Tau repeat domain during aggregation and its effect on neuronal toxicity.

作者信息

Kumar Satish, Tepper Katharina, Kaniyappan Senthilvelrajan, Biernat Jacek, Wegmann Susanne, Mandelkow Eva-Maria, Müller Daniel J, Mandelkow Eckhard

机构信息

From the German Center for Neurodegenerative Diseases (DZNE), 53175 Bonn, Germany, the Max Planck Institute for Neurological Research, Hamburg Outstation, c/o DESY, 22607 Hamburg, Germany, and.

From the German Center for Neurodegenerative Diseases (DZNE), 53175 Bonn, Germany, the Center of Advanced European Studies and Research (CAESAR), 53175 Bonn, Germany.

出版信息

J Biol Chem. 2014 Jul 18;289(29):20318-32. doi: 10.1074/jbc.M114.554725. Epub 2014 May 13.

DOI:10.1074/jbc.M114.554725
PMID:24825901
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4106345/
Abstract

Several neurodegenerative diseases are characterized by the aggregation and posttranslational modifications of Tau protein. Its "repeat domain" (TauRD) is mainly responsible for the aggregation properties, and oligomeric forms are thought to dominate the toxic effects of Tau. Here we investigated the conformational transitions of this domain during oligomerization and aggregation in different states of β-propensity and pseudo-phosphorylation, using several complementary imaging and spectroscopic methods. Although the repeat domain generally aggregates more readily than full-length Tau, its aggregation was greatly slowed down by phosphorylation or pseudo-phosphorylation at the KXGS motifs, concomitant with an extended phase of oligomerization. Analogous effects were observed with pro-aggregant variants of TauRD. Oligomers became most evident in the case of the pro-aggregant mutant TauRDΔK280, as monitored by atomic force microscopy, and the fluorescence lifetime of Alexa-labeled Tau (time-correlated single photon counting (TCSPC)), consistent with its pronounced toxicity in mouse models. In cell models or primary neurons, neither oligomers nor fibrils of TauRD or TauRDΔK280 had a toxic effect, as seen by assays with lactate dehydrogenase and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, respectively. However, oligomers of pro-aggregant TauRDΔK280 specifically caused a loss of spine density in differentiated neurons, indicating a locally restricted impairment of function.

摘要

几种神经退行性疾病的特征是tau蛋白的聚集和翻译后修饰。其“重复结构域”(TauRD)主要负责聚集特性,并且寡聚形式被认为在tau的毒性作用中起主导作用。在这里,我们使用几种互补的成像和光谱方法,研究了该结构域在不同β倾向和假磷酸化状态下寡聚化和聚集过程中的构象转变。尽管重复结构域通常比全长tau更容易聚集,但其聚集在KXGS基序处的磷酸化或假磷酸化作用下大大减慢,同时伴随着寡聚化的延长阶段。在TauRD的促聚集变体中也观察到了类似的效果。通过原子力显微镜监测,在促聚集突变体TauRDΔK280的情况下,寡聚体最为明显,并且Alexa标记的tau的荧光寿命(时间相关单光子计数(TCSPC))也显示了这一点,这与其在小鼠模型中的明显毒性一致。在细胞模型或原代神经元中,分别通过乳酸脱氢酶和3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐测定法可以看出,TauRD或TauRDΔK280的寡聚体和原纤维均没有毒性作用。然而,促聚集TauRDΔK280的寡聚体特异性地导致分化神经元中树突棘密度的丧失,表明功能存在局部受限的损伤。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1978/4106345/f9d8ccf2c354/zbc0301488680007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1978/4106345/48e2cc186f34/zbc0301488680001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1978/4106345/a54c9a05718b/zbc0301488680002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1978/4106345/901f7086791f/zbc0301488680003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1978/4106345/600f16c2ff0d/zbc0301488680004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1978/4106345/ec6f2822cb53/zbc0301488680005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1978/4106345/7cfb3b8797da/zbc0301488680006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1978/4106345/f9d8ccf2c354/zbc0301488680007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1978/4106345/48e2cc186f34/zbc0301488680001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1978/4106345/a54c9a05718b/zbc0301488680002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1978/4106345/901f7086791f/zbc0301488680003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1978/4106345/600f16c2ff0d/zbc0301488680004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1978/4106345/ec6f2822cb53/zbc0301488680005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1978/4106345/7cfb3b8797da/zbc0301488680006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1978/4106345/f9d8ccf2c354/zbc0301488680007.jpg

相似文献

1
Stages and conformations of the Tau repeat domain during aggregation and its effect on neuronal toxicity.Tau重复结构域在聚集过程中的阶段和构象及其对神经元毒性的影响。
J Biol Chem. 2014 Jul 18;289(29):20318-32. doi: 10.1074/jbc.M114.554725. Epub 2014 May 13.
2
Functional networks are impaired by elevated tau-protein but reversible in a regulatable Alzheimer's disease mouse model.功能网络受到升高的 tau 蛋白的损害,但在可调节的阿尔茨海默病小鼠模型中是可逆的。
Mol Neurodegener. 2019 Mar 27;14(1):13. doi: 10.1186/s13024-019-0316-6.
3
Extracellular low-n oligomers of tau cause selective synaptotoxicity without affecting cell viability.细胞外低聚物 tau 导致选择性突触毒性而不影响细胞活力。
Alzheimers Dement. 2017 Nov;13(11):1270-1291. doi: 10.1016/j.jalz.2017.04.002. Epub 2017 May 18.
4
Anti-aggregant tau mutant promotes neurogenesis.抗聚集tau 突变体促进神经发生。
Mol Neurodegener. 2017 Dec 4;12(1):88. doi: 10.1186/s13024-017-0230-8.
5
Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs.Tau重复结构域在tau蛋白病细胞模型中的可诱导表达:聚集对细胞有毒性,但可被抑制剂药物逆转。
J Biol Chem. 2006 Jan 13;281(2):1205-14. doi: 10.1074/jbc.M507753200. Epub 2005 Oct 24.
6
Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model.逐步蛋白酶解会释放出tau片段,这些片段会在神经元细胞模型中引发全长tau的阿尔茨海默氏样聚集。
Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10252-7. doi: 10.1073/pnas.0703676104. Epub 2007 May 29.
7
Competing interactions stabilize pro- and anti-aggregant conformations of human Tau.竞争相互作用稳定了人 Tau 的促聚集和抗聚集构象。
J Biol Chem. 2011 Jun 10;286(23):20512-24. doi: 10.1074/jbc.M111.237875. Epub 2011 Apr 15.
8
Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology.阿尔茨海默病的可调节转基因小鼠模型:tau 病理的发病、可逆性和扩散。
FEBS J. 2013 Sep;280(18):4371-81. doi: 10.1111/febs.12250. Epub 2013 Apr 22.
9
Familial Alzheimer's disease mutations at position 22 of the amyloid β-peptide sequence differentially affect synaptic loss, tau phosphorylation and neuronal cell death in an ex vivo system.淀粉样β肽序列第 22 位的家族性阿尔茨海默病突变在体外系统中不同程度地影响突触丢失、tau 磷酸化和神经元细胞死亡。
PLoS One. 2020 Sep 23;15(9):e0239584. doi: 10.1371/journal.pone.0239584. eCollection 2020.
10
Tauopathies and tau oligomers.tau 病和 tau 寡聚物。
J Alzheimers Dis. 2013;37(3):565-8. doi: 10.3233/JAD-130653.

引用本文的文献

1
Tau Oligomers in Alzheimer's Disease: Modulation Effect of Osmolytes on Amplified Brain-Derived Tau Oligomers.阿尔茨海默病中的tau寡聚体:渗透剂对脑源性tau寡聚体扩增的调节作用
ACS Chem Neurosci. 2025 Aug 6;16(15):2829-2843. doi: 10.1021/acschemneuro.5c00122. Epub 2025 Jul 18.
2
Tau Oligomers Resist Phase Separation.tau寡聚体抗相分离。
Biomolecules. 2025 Feb 26;15(3):336. doi: 10.3390/biom15030336.
3
Drug delivery strategies with lipid-based nanoparticles for Alzheimer's disease treatment.用于阿尔茨海默病治疗的基于脂质纳米颗粒的药物递送策略。

本文引用的文献

1
Extracellular monomeric tau protein is sufficient to initiate the spread of tau protein pathology.细胞外单体tau蛋白足以引发tau蛋白病理学的传播。
J Biol Chem. 2014 Jan 10;289(2):956-67. doi: 10.1074/jbc.M113.515445. Epub 2013 Nov 14.
2
Tau oligomers as potential targets for Alzheimer's diagnosis and novel drugs.作为阿尔茨海默病诊断和新型药物潜在靶点的tau寡聚体
Front Neurol. 2013 Oct 28;4:167. doi: 10.3389/fneur.2013.00167.
3
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls.
J Nanobiotechnology. 2025 Feb 10;23(1):99. doi: 10.1186/s12951-025-03109-3.
4
Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies.tau 蛋白在神经退行性疾病中的作用:分子机制、生物标志物和治疗策略。
Transl Neurodegener. 2024 Aug 6;13(1):40. doi: 10.1186/s40035-024-00429-6.
5
Development of an anti-tauopathy mucosal vaccine specifically targeting pathologic conformers.一种特异性靶向病理构象体的抗tau蛋白病黏膜疫苗的研发。
NPJ Vaccines. 2024 Jun 15;9(1):108. doi: 10.1038/s41541-024-00904-1.
6
Novel ultrasensitive immunoassay for the selective quantification of tau oligomers and related soluble aggregates.新型超敏免疫分析法用于 tau 寡聚体及其相关可溶性聚集物的选择性定量检测
Alzheimers Dement. 2024 Apr;20(4):2894-2905. doi: 10.1002/alz.13711. Epub 2024 Mar 23.
7
Untangling Tau: Molecular Insights into Neuroinflammation, Pathophysiology, and Emerging Immunotherapies.解析Tau蛋白:对神经炎症、病理生理学及新兴免疫疗法的分子见解
Curr Issues Mol Biol. 2023 Nov 2;45(11):8816-8839. doi: 10.3390/cimb45110553.
8
Espresso Coffee Mitigates the Aggregation and Condensation of Alzheimer's Associated Tau Protein.浓咖啡可减轻阿尔茨海默病相关 Tau 蛋白的聚集和凝聚。
J Agric Food Chem. 2023 Aug 2;71(30):11429-11441. doi: 10.1021/acs.jafc.3c01072. Epub 2023 Jul 19.
9
A Validated Method to Prepare Stable Tau Oligomers.一种稳定的 Tau 寡聚物的验证方法。
Methods Mol Biol. 2023;2551:203-224. doi: 10.1007/978-1-0716-2597-2_14.
10
Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease.tau 聚集抑制肽作为阿尔茨海默病的潜在治疗方法。
Cell Mol Neurobiol. 2023 Apr;43(3):951-961. doi: 10.1007/s10571-022-01230-7. Epub 2022 May 21.
tau 病小鼠模型和阿尔茨海默病患者与正常对照的 tau 病理学成像比较。
Neuron. 2013 Sep 18;79(6):1094-108. doi: 10.1016/j.neuron.2013.07.037.
4
Potential synergy between tau aggregation inhibitors and tau chaperone modulators.tau聚集抑制剂与tau伴侣调节剂之间的潜在协同作用。
Alzheimers Res Ther. 2013 Sep 16;5(5):41. doi: 10.1186/alzrt207. eCollection 2013.
5
Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds.硫酸乙酰肝素蛋白聚糖介导特定蛋白构象种子的内化和传播。
Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):E3138-47. doi: 10.1073/pnas.1301440110. Epub 2013 Jul 29.
6
Characteristics of tau oligomers.tau 寡聚物的特征。
Front Neurol. 2013 Jul 19;4:102. doi: 10.3389/fneur.2013.00102. eCollection 2013.
7
Tau pathology and neurodegeneration.tau 病理学与神经退行性变。
Lancet Neurol. 2013 Jun;12(6):609-22. doi: 10.1016/S1474-4422(13)70090-5.
8
Protein amyloids develop an intrinsic fluorescence signature during aggregation.蛋白质淀粉样纤维在聚集过程中会产生固有荧光特征。
Analyst. 2013 Apr 7;138(7):2156-62. doi: 10.1039/c3an36798c. Epub 2013 Feb 18.
9
Physiological release of endogenous tau is stimulated by neuronal activity.内源性 tau 的生理释放受神经元活动的刺激。
EMBO Rep. 2013 Apr;14(4):389-94. doi: 10.1038/embor.2013.15. Epub 2013 Feb 15.
10
Inhibition of tau filament formation by conformational modulation.通过构象调节抑制 tau 丝形成。
J Am Chem Soc. 2013 Feb 20;135(7):2853-62. doi: 10.1021/ja312471h. Epub 2013 Feb 5.